UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)

Clinical cancer research, 2019-09, Vol.25 (18), p.5485-5492

2019

Volltextzugriff (PDF)

The Development of a Skin Cancer Classification System for Pigmented Skin Lesions Using Deep Learning

Biomolecules (Basel, Switzerland), 2020-07, Vol.10 (8), p.1123

2020

Volltextzugriff (PDF)

Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab

Cancer science, 2018-11, Vol.109 (11), p.3583-3590

2018

Volltextzugriff (PDF)

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Journal of thoracic oncology, 2022-02, Vol.17 (2), p.289-308

2022

Volltextzugriff (PDF)

Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study

European journal of cancer (1990), 2019-05, Vol.113, p.78-86

2019

Volltextzugriff (PDF)

Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice

Cancer science, 2022-12, Vol.113 (12), p.4300-4310

2022

Volltextzugriff (PDF)

Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma

Lung cancer (Amsterdam, Netherlands), 2015-05, Vol.88 (2), p.154-159

2015

Volltextzugriff (PDF)

Nivolumab-induced autoimmune encephalitis in an anti-neuronal autoantibody-positive patient

Japanese journal of clinical oncology, 2019-08, Vol.49 (8), p.793-794

2019

Volltextzugriff (PDF)

History of Japan Clinical Oncology Group (JCOG) Lung Cancer Study Group

Japanese journal of clinical oncology, 2020-05, Vol.50 (5), p.502-511

2020

Volltextzugriff (PDF)

Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions

Scientific reports, 2021-09, Vol.11 (1), p.18762-18762, Article 18762

2021

Volltextzugriff (PDF)

CD20+ tumor‐infiltrating immune cells and CD204+ M2 macrophages are associated with prognosis in thymic carcinoma

Cancer science, 2020-06, Vol.111 (6), p.1921-1932

2020

Volltextzugriff (PDF)

Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients

Japanese journal of clinical oncology, 2021-07, Vol.51 (7), p.1114-1122

2021

Volltextzugriff (PDF)

Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer

PloS one, 2014-07, Vol.9 (7), p.e102436

2014

Volltextzugriff (PDF)

Real‐world safety of nivolumab in patients with non‐small‐cell lung cancer in Japan: Postmarketing surveillance

Cancer science, 2021-11, Vol.112 (11), p.4692-4701

2021

Volltextzugriff (PDF)

Diagnostic efficacy of cryobiopsy for peripheral pulmonary lesions: A propensity score analysis

Lung cancer (Amsterdam, Netherlands), 2023-04, Vol.178, p.220-228

2023

Volltextzugriff (PDF)

Diagnostic Outcomes and Safety of Cryobiopsy Added to Conventional Sampling Methods

Chest, 2021-11, Vol.160 (5), p.1890-1901

2021

Volltextzugriff (PDF)

Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort

Lung cancer (Amsterdam, Netherlands), 2018-03, Vol.117, p.14-19

2018

Volltextzugriff (PDF)

Medical management of older patients with lung cancer

Japanese journal of clinical oncology, 2022-10, Vol.52 (10), p.1082-1088

2022

Volltextzugriff (PDF)

RB1 loss induced small cell lung cancer transformation as acquired resistance to pembrolizumab in an advanced NSCLC patient

Lung cancer (Amsterdam, Netherlands), 2021-01, Vol.151, p.101-103

2021

Volltextzugriff (PDF)

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies

Cancer chemotherapy and pharmacology, 2016-04, Vol.77 (4), p.767-776

2016

Volltextzugriff (PDF)

Insulinoma-associated-1 (INSM1) expression in thymic squamous cell carcinoma

Virchows Archiv : an international journal of pathology, 2022-12, Vol.481 (6), p.893-901

2022

Volltextzugriff (PDF)

Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy

Lung cancer (Amsterdam, Netherlands), 2016-09, Vol.99, p.4-10

2016

Volltextzugriff (PDF)

Association between genetic variants and the risk of nivolumab-induced immune-related adverse events

Pharmacogenomics, 2022-11, Vol.23 (16), p.887-901

2022

Volltextzugriff (PDF)

Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease

PloS one, 2019-10, Vol.14 (10), p.e0223371

2019

Volltextzugriff (PDF)

Feasibility study of cryobiopsy for practical pathological diagnosis of primary lung cancer including immunohistochemical assessment

Japanese journal of clinical oncology, 2021-02, Vol.51 (2), p.271-278

2021

Volltextzugriff (PDF)

1 – 25 von 531

Suche als RSS-Feed

Aktive Filter

ThemaLung Neoplasms - Drug Therapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(459)
Mit Volltextzugriff
(501)

Publikationsform

Sprache

Englisch
(489)
Japanisch
(129)
Koreanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)

The Development of a Skin Cancer Classification System for Pigmented Skin Lesions Using Deep Learning

Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study

Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice

Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma

Nivolumab-induced autoimmune encephalitis in an anti-neuronal autoantibody-positive patient

History of Japan Clinical Oncology Group (JCOG) Lung Cancer Study Group

Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions

CD20+ tumor‐infiltrating immune cells and CD204+ M2 macrophages are associated with prognosis in thymic carcinoma

Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients

Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer

Real‐world safety of nivolumab in patients with non‐small‐cell lung cancer in Japan: Postmarketing surveillance

Diagnostic efficacy of cryobiopsy for peripheral pulmonary lesions: A propensity score analysis

Diagnostic Outcomes and Safety of Cryobiopsy Added to Conventional Sampling Methods

Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort

Medical management of older patients with lung cancer

RB1 loss induced small cell lung cancer transformation as acquired resistance to pembrolizumab in an advanced NSCLC patient

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies

Insulinoma-associated-1 (INSM1) expression in thymic squamous cell carcinoma

Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy

Association between genetic variants and the risk of nivolumab-induced immune-related adverse events

Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease

Feasibility study of cryobiopsy for practical pathological diagnosis of primary lung cancer including immunohistochemical assessment

Aktive Filter

Suchergebnisse filtern